Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials

被引:26
|
作者
Privitera, Michael [1 ]
Bhathal, Hari [2 ]
Wong, Matthew [3 ]
Cross, J. Helen [4 ]
Wirrell, Elaine [5 ]
Marsh, Eric D. [6 ]
Mazurkiewicz-Beldzinska, Maria [7 ]
Villanueva, Vicente [8 ]
Checketts, Daniel [9 ]
Knappertz, Volker [10 ]
VanLandingham, Kevan [10 ]
机构
[1] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA
[2] Neuroctr Barcelona, Teknon Med Ctr, Barcelona, Spain
[3] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[4] UCL, Great Ormond St Inst Child Hlth, Natl Inst Hlth Res, Biomed Res Ctr, London, England
[5] Mayo Clin, Rochester, MN USA
[6] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[7] Med Univ Gdansk, Gdansk, Poland
[8] Univ & Polytech Hosp La Fe, Valencia, Spain
[9] GW Res Ltd, Cambridge, England
[10] Greenwich Biosci Inc, Carlsbad, CA USA
关键词
antiepileptic drug; antiseizure medication; childhood onset epilepsy; drop seizures; treatment‐ resistant epilepsy;
D O I
10.1111/epi.16878
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), we conducted post hoc analyses of data from two randomized, placebo-controlled, Phase 3 trials, GWPCARE3 (NCT02224560) and GWPCARE4 (NCT02224690), of patients with Lennox-Gastaut syndrome. Methods Patients received plant-derived pharmaceutical formulation of highly purified CBD (Epidiolex, 100 mg/ml oral solution) at 10 mg/kg/day (CBD10; GWPCARE3) or 20 mg/kg/day (CBD20; both trials) or placebo for 14 weeks. Treatment started at 2.5 mg/kg/day for all groups and reached 10 mg/kg/day on Day 7 and 20 mg/kg/day (CBD20 and matching placebo only) on Day 11. Percentage change from baseline in drop seizure frequency was calculated by cumulative day (i.e., including all previous days). Time to onset and resolution of AEs were evaluated. Results Overall, 235 patients received CBD (CBD10 [GWPCARE3 only], n = 67; CBD20 [pooled GWPCARE3&4], n = 168) and 161 received placebo. Mean (range) age was 15.3 years (2.6-48.0). Patients had previously discontinued a median (range) of six (0-28) antiepileptic drugs (AEDs) and were currently taking a median of three (0-5) AEDs. Differences in drop seizure reduction between placebo and CBD emerged during the titration period and became nominally significant by Day 6 (p = .008) for pooled CBD treatment groups. Separation between placebo and CBD in >= 50% responder rate emerged by Day 6. Onset of the first reported AE occurred during the titration period in 45% of patients (CBD10, 46%; CBD20, 52%; placebo, 38%). In patients with AEs, resolution occurred within 4 weeks of onset in 53% of placebo and 39% of CBD patients and by end of study in 63% of placebo and 61% of CBD patients. Significance Treatment effect (efficacy and AEs) of CBD may occur within 1 week of starting treatment. Although AEs lasted longer for CBD than placebo, most resolved within the 14-week period.
引用
收藏
页码:1130 / 1140
页数:11
相关论文
共 50 条
  • [21] Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
    Silvinato, Antonio
    Floriano, Idevaldo
    Bernardo, Wanderley Marques
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2022, 68 (10): : 1345 - 1357
  • [22] Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice
    Striano, Pasquale
    McMurray, Rob
    Santamarina, Estevo
    Falip, Merce
    EPILEPTIC DISORDERS, 2018, 20 (01) : 13 - 29
  • [23] Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam in patients with Lennox-Gastaut syndrome or Dravet syndrome: Interim analysis
    Nortvedt, C.
    Bast, T.
    Pulitano, P.
    Soto, V.
    Toulouse, J.
    Fuller, D. S.
    EPILEPSIA, 2022, 63 : 134 - 134
  • [24] USE OF CANNABIDIOL (RSHO) IN THE TREATMENT OF REFRACTORY EPILEPSY (LENNOX-GASTAUT SYNDROME), EXPERIENCE OF 38 CASES
    Garza Morales, S. J.
    Benavides Aguilar, O.
    Bastida Mercado, E.
    EPILEPSIA, 2017, 58 : S53 - S53
  • [25] Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome
    Iannone, Luigi Francesco
    Arena, Gabriele
    Battaglia, Domenica
    Bisulli, Francesca
    Bonanni, Paolo
    Boni, Antonella
    Canevini, Maria Paola
    Cantalupo, Gaetano
    Cesaroni, Elisabetta
    Contin, Manuela
    Coppola, Antonietta
    Cordelli, Duccio Maria
    Cricchiuti, Giovanni
    De Giorgis, Valentina
    De Leva, Maria Fulvia
    De Rinaldis, Marta
    d'Orsi, Giuseppe
    Elia, Maurizio
    Galimberti, Carlo Andrea
    Morano, Alessandra
    Granata, Tiziana
    Guerrini, Renzo
    Lodi, Monica A. M.
    La Neve, Angela
    Marchese, Francesca
    Masnada, Silvia
    Michelucci, Roberto
    Nosadini, Margherita
    Pilolli, Nicola
    Pruna, Dario
    Ragona, Francesca
    Rosati, Anna
    Santucci, Margherita
    Spalice, Alberto
    Pietrafusa, Nicola
    Striano, Pasquale
    Tartara, Elena
    Tassi, Laura
    Papa, Amanda
    Zucca, Claudio
    Russo, Emilio
    Mecarelli, Oriano
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [26] Topiramate in Lennox-Gastaut syndrome: Open-label treatment of patients completing a randomized controlled trial
    Glauser, TA
    Levisohn, PM
    Ritter, F
    Sachdeo, RC
    EPILEPSIA, 2000, 41 : S86 - S90
  • [27] Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study
    Thiele, Elizabeth
    Marsh, Eric
    Mazurkiewicz-Beldzinska, Maria
    Halford, Jonathan J.
    Gunning, Boudewijn
    Devinsky, Orrin
    Checketts, Daniel
    Roberts, Claire
    EPILEPSIA, 2019, 60 (03) : 419 - 428
  • [28] Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome
    Nabbout, Rima
    Arzimanoglou, Alexis
    Auvin, Stephane
    Berquin, Patrick
    Desurkar, Archana
    Fuller, Douglas
    Nortvedt, Charlotte
    Pulitano, Patrizia
    Rosati, Anna
    Soto, Victor
    Villanueva, Vicente
    Cross, J. Helen
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2023, 110 : 78 - 85
  • [29] BUDGET IMPACT ANALYSIS OF ANTIEPILEPTIC DRUGS IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME
    Skornicki, M.
    Clements, K. M.
    O'Sullivan, A. K.
    VALUE IN HEALTH, 2012, 15 (04) : A141 - A142
  • [30] Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain
    Garcia-Penas, Juan J.
    Nagel-Rein, Antonio Gil
    Sanchez-Carpintero, Rocio
    Villanueva-Haba, Vicente
    REVISTA DE NEUROLOGIA, 2021, 73 : S1 - S8